Stock vs Stock Comparison

The Cigna Group vs Abbott Laboratories

CI and ABT are evenly matched across key metrics.

CI$270.73
ABT$86.99

🏆 Tale of the Tape

44
CIABT
2.2%Profitability (Net Margin)14.7%
2.4xValuation (P/E)24.0x
4.6%Efficiency (ROIC)10.1%
5/9Health (Piotroski F)5/9
2.7Safety (Altman Z)4.9
12.5%Growth (Rev YoY)5.7%
-0.38Risk (Sharpe 1Y)-1.05
2.77xBalance Sheet (D/E)0.64x
8.77%FCF Yield4.21%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.260
252-Day Correlation
0.207
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricCIABT
Market Cap$73.4B$149.1B
P/E Ratio2.4x24.0x
Forward P/E8.3x14.1x
P/B1.74x2.86x
Dividend Yield2.25%2.94%
Beta0.310.65

Quantitative Metrics

MetricCIABT
DCF Fair Value$608.57$57.20
DCF Upside+121.2%-43.2%
Piotroski F5/95/9
Altman Z2.734.87
Beneish M-2.53
FCF Yield8.77%4.21%
Net Debt/EBITDA1.9x0.1x
ROIC4.6%10.1%
WACC6.8%9.4%
ROIC – WACC-2.2pp0.7pp
Gross Margin56.4%
Net Margin2.2%14.7%
Rev Growth YoY12.5%5.7%
Sharpe (1Y)-0.38-1.05
Max Drawdown 3Y
FCF Payout Ratio19%56%

CI Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

CI found in:

XHS1.94%
XLV1.39%
VHT1.26%
VFVA0.89%
ONEV0.78%
ONEO0.43%
MGV0.38%
VYM0.32%
VTV0.30%
SCHV0.26%
SPYV0.26%
QUS0.24%
VONV0.22%
IWD0.21%
RSP0.20%
ESGV0.14%
SPLG0.14%
IVV0.13%
SCHX0.12%
VONE0.12%
VOO0.12%
SCHB0.12%
SPY0.12%
ITOT0.11%
VTI0.11%
SPTM0.11%
URTH0.09%
ACWI0.07%
VT0.07%
IWF0.02%
VONG0.02%

ABT found in:

IHI16.06%
IYH2.88%
XLV2.85%
VHT2.55%
DGRW1.71%
XHE1.36%
NOBL1.34%
SDY0.99%
MGV0.78%
VIG0.71%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.61%
IWD0.58%
QUS0.57%
SPYV0.53%
VONV0.48%
IVV0.37%
SPLG0.37%
ESGV0.36%
ITOT0.33%
SCHX0.33%
SCHB0.30%
VOO0.26%
VONE0.24%
SPY0.24%
URTH0.24%
VTI0.23%
SPTM0.22%
ACWI0.20%
RSP0.17%
VT0.14%
ONEO0.08%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CI vs ABT: Head-to-Head Analysis

The Cigna Group (CI) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. Our quantitative Tale of the Tape shows these companies are evenly matched across profitability, valuation, and risk metrics.

In terms of capital efficiency, CI generates a return on invested capital (ROIC) of 4.6% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between CI and ABT is 0.260, indicating low correlation, making them an effective diversification pair in a portfolio context.

CI appears in 31 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CI or ABT?

Our quantitative analysis compares CI and ABT across nine fundamental dimensions. CI and ABT are evenly matched across key metrics. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CI and ABT correlated?

The 252-day correlation between CI and ABT is 0.260. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.